Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Mantle Cell Lymphoma (MCL) is a malignancy with a poor response to treatment and with a
median survival of 2- 4 years since diagnosis. Although histology is similar to that of an
indolent lymphoma, MCL is currently considered an aggressive tumour. Few prospective
therapeutic trials have been reported in MCL, and results are difficult to interpret due to
treatment heterogeneity. It is known that standard chemotherapy for other clinically
aggressive lymphomas yields poor results. Recently, better results have been communicated
with intense induction chemotherapy treatments or consolidating the response with high dose
chemotherapy with stem cell support. Keeping in mind these considerations, we will use and
intensive induction treatment with Hyper-CVAD/MTX-AraC associated with anti-CD20 in order to
increase the overall response rate followed by consolidation treatment with Ibritumomab
-tiuxetan (Zevalin) with the aim of eradicate the minimal residual disease, responsible of
relapse.
Phase:
Phase 2
Details
Lead Sponsor:
CABYC
Collaborator:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea